As a consequence of the effects of cabergoline on insulin secretion and peripheral sensitivity, prevalence of metabolic syndrome reduces from 32 to 10% (40, 42, 43, 47) of patients with hypeprolactinemia receiving long-term therapy. This evidence concerns the gene INS and metabolic syndrome.